Observational studyBMC infectious diseases2026
Comparative evaluation of Hepassocin, DCP, and AFP-L3 for non-invasive assessment of liver fibrosis in Hepatitis B infection.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection often leads to progressive liver fibrosis, which may remain undetected until irreversible hepatic damage occurs. This study evaluated Hepassocin (HPS), des-gamma-carboxy Prothrombin (DCP) and Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) as serological indicators associated with APRI-defined fibrosis risk in HBV infection.
methodsThis observational study included 150 HBsAg-positive patients (acute and chronic HBV) and 50 healthy controls. Serum concentrations of HPS, DCP and AFP-L3 were quantified using ELISA alongside routine liver function tests. Fibrosis risk was evaluated with the AST-to-Platelet Ratio Index (APRI) and classified based on recognized clinical cut-offs. Group comparisons using non-parametric testing, correlations were assessed by Spearman correlation and binary logistic regression was applied to identify independent predictors of severe fibrosis. Diagnostic accuracy was assessed using ROC analysis.
resultsHBV patients exhibited significantly altered liver biochemistry, including elevated liver enzymes, reduced platelet counts, higher APRI scores, and increased serum levels of all three biomarkers compared with controls. HPS and DCP levels increased progressively across APRI-defined fibrosis categories, whereas AFP-L3 showed limited discriminatory ability. Multivariate analysis identified HPS and DCP as biomarkers independently associated with higher APRI-defined fibrosis risk, while AFP-L3 lacked independent predictive value. ROC analysis showed that HPS and DCP demonstrated good discrimination for higher APRI-defined fibrosis risk categories within the study population, and their combined use further improved diagnostic performance. The integrated HPS + DCP model demonstrated the highest discriminatory performance within APRI-based fibrosis risk stratification (AUC = 0.935).
conclusionHPS and DCP are potential non-invasive biomarkers associated with APRI-defined fibrosis risk in HBV infection and showed superior predictive performance compared with AFP-L3 and routine biochemical markers within APRI-based fibrosis stratification. Their combined application may enhance APRI-based fibrosis risk stratification; however, these findings should be considered preliminary and require validation in independent cohorts using accepted fibrosis reference standards before clinical adoption can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.